



A conference that is for us and by us

Emergency Medicine Pharmacotherapy with Resuscitation (EMPowerRx) Conference





A conference that is for us and by us

When Lido-CAN! Amiodarone vs Lidocaine in Cardiac Arrest

Katelyn Corcoran, PharmD

PGY2 Emergency Medicine Pharmacy resident


AdventHealth Orlando

Lidocaine

- Class Ib
Antiarrhythmic
- Dose: 1-1.5 mg/kg
- Preparation: Prefilled syringe 100 mg/5 ml
 - Proper weight based first dose for 66.7-100 kg

Circulation. 2021;144:823-839.
Circulation. 2018;138:e272-e391.


Image from Wikimedia; original author Quasar, derivative work by Mnoke and Silvia3:



Guideline Updates

2010 ACC/AHA

If amiodarone is unavailable, lidocaine may be considered...not been demonstrated to improve rates of ROSC and hospital admission (Class IIb, LOE B)



2020 ACC/AHA

We suggest the use of amiodarone or lidocaine in adults with shock-refractory VF/pVT (weak recommendation, low certainty evidence)

ROC-ALPS Trial



- Treated with:
 - Amiodarone 300 mg IV
 - Lidocaine 120mg IV
 - 0.9% Normal Saline IV



- Shock-refractory ventricular fibrillation
- Shock-refractory pulseless ventricular tachycardia



- Primary: Survival to hospital discharge
- Secondary: Favorable neurologic function at discharge

ROC-ALPS Trial

Primary: Survival
to Hospital
Discharge

Amiodarone:
24.4%

Lidocaine:
23.7%

Placebo: 21%

Secondary:
Survival with
MRS ≤ 3

Amiodarone:
18.8%

Lidocaine:
17.5%

Placebo:
16.6%

Subgroup:
Witnessed
Arrest

Amiodarone:
27.7%

Lidocaine:
27.8%

Placebo:
22.7%

Adverse Events:
Seizure

Amiodarone:
3.2%

Lidocaine:
5.1%

Placebo: 3.7%

N Engl J Med. 2002 Mar 21;346(12):884-90.
Am Heart J. 2014 May ; 167(5): 653-659.e4

Am J Cardiol 2002;90:853- 859
N Engl J Med 2016; 374:1711-1722



A conference that is for us and by us

When Lido-CAN! Amiodarone vs Lidocaine in Cardiac Arrest

Cardiac Arrest

Katelyn Corcoran, PharmD

PGY2 Emergency Medicine Pharmacy resident

AdventHealth Orlando

Special Patient Populations



Ma's Home Med List

- Lisinopril
- Atorvastatin
- Apixaban
- **Dofetilide**



Toxicol Rep. 2018; 5: 357-362.

J Pharm Pract 2021 May 13;8971900211015053